TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB92420

Peptide_Name

Longicalycinin A cyclic analogue 7

Activity

Antibacterial Anticancer Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

Peptipedia CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 5-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia and CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Cyclized N-terminal: Cyclized

Sequence

PYVFA

FASTA

>TPDB92420|Antibacterial;Anticancer;Toxicity|length=5
PYVFA

Formula C31H41N5O7

Absent Amino Acids RNDCEQGHILKMSTW

Common Amino Acids AFPYV

Mass 595.70

PI 5.94

Basic Residues 0

Acidic Residues 0

Hydrophobic Residues 4

Net Charge -0

Boman Index -1.72

Hydrophobicity 1.180

Aliphatic Index 78.00

Half Life

Mammalian: >20 hour Yeast: >20 hour E.coli: ?

Extinction Coefficient Cystines 1490

Absorbance 280nm 250.13

Polar Residues 1

number

1

A

0

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

0

I

0

L

0

K

0

M

1

F

1

P

0

S

0

T

0

W

1

Y

1

V

Amino Acid Distribution

A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 0 K: 0 M: 0 F: 1 P: 1 S: 0 T: 0 W: 0 Y: 1 V: 1

Length

5

Formula

C31H41N5O7

Mass

595.70

PI

5.94

Net Charge

-0

Boman Index

-1.72

Hydrophobicity

1.180

C_terminal_Modification

Cyclized

Chirality

L

Linear_or_Cyclic

Cyclic

N_terminal_Modification

Cyclized

Nature

Anticancer

Origin

Synthetic Analogue of Longicalycinin A

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 9.21 ± 0.0056 µg/ml

Detail Source Activity Anticancer

Activity Measurement 9.21

Target

Cancer Type Liver Cancer

Cell Line HepG-2

Tissue Affected Liver

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 12.11 ± 0.0035 µg/ml

Detail Source Activity Anticancer

Activity Measurement 12.11

Target

Cancer Type Colorectal Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Evidence 3 Activity

Activity

Activity Raw

47.68% Cell death at 100 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Liver Cancer

Cell Line HepG-2

Tissue Affected Liver

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020

Evidence 4 Activity

Activity

Activity Raw

22.86% Cell death at 100 µg/ml

Detail Source Activity Anticancer

Target

Cancer Type Colorectal Cancer

Cell Line HT-29

Tissue Affected Colon

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2020